Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 May;39(5):1114–1119. doi: 10.1128/aac.39.5.1114

Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model.

H J Field 1, D Tewari 1, D Sutton 1, A M Thackray 1
PMCID: PMC162693  PMID: 7625798

Abstract

A mouse model of herpes simplex virus type 1 infection in an immunocompromised host was established by using cyclosporin-A to impair T-cell function. Following inoculation of herpes simplex virus type 1 into the skin of the ear pinna, cyclosporin-A prolonged virus replication in the skin and neural tissues compared with that in immunocompetent mice. This model was used to investigate the activity of famciclovir (FCV) and valaciclovir (VACV), which are oral products of the antiherpesvirus agents penciclovir and acyclovir, respectively. Both prodrugs gave similar blood profiles of the antiherpesvirus agents in normal and cyclosporin-treated mice. The compounds were administered by the oral route at 50 mg/kg per dose twice daily for 5 days. Both compounds were very effective at clearing infectious virus from the tissues despite the immunosuppression; FCV-treated animals cleared virus from the ear pinna more rapidly than VACV-treated animals. The areas under the concentration-time curve (AUC) for virus replication with time were reduced to 50 and 30% of control values for ear pinna and brain stem, respectively, with VACV therapy and to < 5% in both tissues by FCV. When treatment was continued to day 10, the reductions in AUC for ear and brain stem, respectively, were to 33 and 26% of control values with VACV and to < 3 and < 5% with FCV. However, on cessation of the antiviral treatment, there was a reproducible recurrence of infectious virus in the tissues obtained from VACV-treated mice. The recurrence of infectious virus was also evident after 10 days of treatment with VACV. In mice which had received FCV for 10 or 5 days, these was no resumption of virus replication in the ear pinna or brain stem. When dosing was reduced to once per day, both compounds were less effective at controlling the infection. Nevertheless, no recurrence of infectious virus was observed on cessation of FCV therapy.

Full Text

The Full Text of this article is available as a PDF (221.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett W. M., Pulliam J. P. Cyclosporine nephrotoxicity. Ann Intern Med. 1983 Dec;99(6):851–854. doi: 10.7326/0003-4819-99-6-851. [DOI] [PubMed] [Google Scholar]
  2. Earnshaw D. L., Bacon T. H., Darlison S. J., Edmonds K., Perkins R. M., Vere Hodge R. A. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother. 1992 Dec;36(12):2747–2757. doi: 10.1128/aac.36.12.2747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ellis M. N., Martin J. L., Lobe D. C., Johnsrude J. D., Barry D. W. Induction of acyclovir-resistant mutants of herpes simplex virus type I in athymic nude mice. J Antimicrob Chemother. 1986 Oct;18 (Suppl B):95–101. doi: 10.1093/jac/18.supplement_b.95. [DOI] [PubMed] [Google Scholar]
  4. Field H. J., Bell S. E., Elion G. B., Nash A. A., Wildy P. Effect of acycloguanosine treatment of acute and latent herpes simplex infections in mice. Antimicrob Agents Chemother. 1979 Apr;15(4):554–561. doi: 10.1128/aac.15.4.554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Field H. J., Goldthorpe S. E. Antiviral drug resistance. Trends Pharmacol Sci. 1989 Aug;10(8):333–337. doi: 10.1016/0165-6147(89)90069-2. [DOI] [PubMed] [Google Scholar]
  6. Harnden M. R., Jarvest R. L., Boyd M. R., Sutton D., Vere Hodge R. A. Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties. J Med Chem. 1989 Aug;32(8):1738–1743. doi: 10.1021/jm00128a012. [DOI] [PubMed] [Google Scholar]
  7. Hill T. J., Field H. J., Blyth W. A. Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease. J Gen Virol. 1975 Sep;28(3):341–353. doi: 10.1099/0022-1317-28-3-341. [DOI] [PubMed] [Google Scholar]
  8. Hodge R. A., Perkins R. M. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother. 1989 Feb;33(2):223–229. doi: 10.1128/aac.33.2.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jeffries D. J. The spectrum of cytomegalovirus infection and its management. J Antimicrob Chemother. 1989 Jun;23 (Suppl E):1–10. doi: 10.1093/jac/23.suppl_e.1. [DOI] [PubMed] [Google Scholar]
  10. Kahan B. D. Cyclosporine. N Engl J Med. 1989 Dec 21;321(25):1725–1738. doi: 10.1056/NEJM198912213212507. [DOI] [PubMed] [Google Scholar]
  11. Maclean H., Dhillon B. Cytomegalovirus retinitis: diagnosis and treatment. Int J STD AIDS. 1993 Nov-Dec;4(6):322–325. doi: 10.1177/095646249300400603. [DOI] [PubMed] [Google Scholar]
  12. Meyers J. D., Flournoy N., Sanders J. E., McGuffin R. W., Newton B. A., Fisher L. D., Lum L. G., Appelbaum F. R., Doney K., Sullivan K. M. Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann Intern Med. 1987 Dec;107(6):809–816. doi: 10.7326/0003-4819-107-6-809. [DOI] [PubMed] [Google Scholar]
  13. Nash A. A., Field H. J., Quartey-Papafio R. Cell-mediated immunity in herpes simplex virus-infected mice: induction, characterization and antiviral effects of delayed type hypersensitivity. J Gen Virol. 1980 Jun;48(Pt 2):351–357. doi: 10.1099/0022-1317-48-2-351. [DOI] [PubMed] [Google Scholar]
  14. Sutton D., Boyd M. R. Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. Antimicrob Agents Chemother. 1993 Apr;37(4):642–645. doi: 10.1128/aac.37.4.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tewari D., Whalley J. M., Love D. N., Field H. J. Characterization of immune responses to baculovirus-expressed equine herpesvirus type 1 glycoproteins D and H in a murine model. J Gen Virol. 1994 Jul;75(Pt 7):1735–1741. doi: 10.1099/0022-1317-75-7-1735. [DOI] [PubMed] [Google Scholar]
  16. Thomson M. H., Jeffries D. J. Ganciclovir therapy in iatrogenically immunosuppressed patients with cytomegalovirus disease. J Antimicrob Chemother. 1989 Jun;23 (Suppl E):61–70. doi: 10.1093/jac/23.suppl_e.61. [DOI] [PubMed] [Google Scholar]
  17. Tilson H. H., Engle C. R., Andrews E. B. Safety of acyclovir: a summary of the first 10 years experience. J Med Virol. 1993;Suppl 1:67–73. doi: 10.1002/jmv.1890410513. [DOI] [PubMed] [Google Scholar]
  18. Vere Hodge R. A., Sutton D., Boyd M. R., Harnden M. R., Jarvest R. L. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother. 1989 Oct;33(10):1765–1773. doi: 10.1128/aac.33.10.1765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Vere Hodge R. A., Sutton D., Boyd M. R., Harnden M. R., Jarvest R. L. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother. 1989 Oct;33(10):1765–1773. doi: 10.1128/aac.33.10.1765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Weller S., Blum M. R., Doucette M., Burnette T., Cederberg D. M., de Miranda P., Smiley M. L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993 Dec;54(6):595–605. doi: 10.1038/clpt.1993.196. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES